GMP IPO
📋 Filings Intelligence
About Contact
LIVE — Auto-updated every 10 mins · Equity segment
Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement — financial results, order wins, dividends, mergers and more. Updated live.

—
Filed today
—
Companies tracked
NSE & BSE
Listed on
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings —

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
Jagsonpal Pharmaceuticals Ltd

Jagsonpal Pharma Q2 FY27 Standalone Revenue at Rs. 813.75 Million

RESULTS ◆ Monitor Closely LOW RISK
📅 Filed on BSE: 28 Oct 2026, 06:20 PM IST  ·  BSE ID: e3b1e473-62b5-4aa4-8ead-c57c43b34ebb
View Original BSE Filing (PDF)
💡
In Simple Terms
Jagsonpal Pharmaceuticals announced its latest financial results, showing Rs. 813.75 Million in quarterly revenue and Rs. 123.88 Million profit.
🤖 AI Summary
  • Jagsonpal Pharmaceuticals reported standalone revenue from operations of Rs. 813.75 Million for Q2 FY27.
  • Standalone total comprehensive income for the quarter ended September 30, 2026, was Rs. 123.88 Million.
  • Basic Earnings Per Share (EPS) for the second quarter of FY27 stood at Rs. 1.91.
  • For the half-year ended September 30, 2026, standalone revenue was Rs. 1,636.07 Million.
  • The Board of Directors approved the unaudited standalone and consolidated financial results on October 28, 2026.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Standalone Revenue from operations (Q2 FY27)
813.75 Million
9.28%
Standalone Total Income (Q2 FY27)
836.06 Million
7.83%
Standalone Total Comprehensive Income (Q2 FY27)
123.88 Million
(2.79%)
Standalone Basic EPS (Q2 FY27)
1.91 Rs.
1.60%
Standalone Revenue from operations (H1 FY27)
1,636.07 Million
8.99%
Standalone Total Comprehensive Income (H1 FY27)
256.71 Million
8.79%
Standalone Basic EPS (H1 FY27)
3.91 Rs.
11.71%
🏢 How This Affects the Company
💰
Financial Impact
The company's standalone revenue from operations for the half year ended September 30, 2026, increased to Rs. 1,636.07 Million from Rs. 1,500.77 Million in the prior comparable period. Total comprehensive income for the half year also increased to Rs. 256.71 Million from Rs. 235.96 Million.
👥 What This Means For Shareholders
✅
Action Required
No action required from shareholders based on this financial results filing.
👤
Who Is Affected
All existing shareholders are affected by the company's financial performance, specifically the reported basic EPS of Rs. 1.91 for Q2 FY27 and Rs. 3.91 for H1 FY27.
🔍
Management Signal
The timely disclosure of unaudited financial results signals adherence to regulatory compliance and transparency regarding quarterly performance.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List — track these upcoming events
Q3 FY27 standalone results — observe revenue trends and profitability.
Updates on employee benefits expense adjustments related to New Labour Codes.
Any further details on acquisitions if driving consolidated revenue growth.
LOW RISK The filing reports routine financial results; no new specific risks are introduced.
💡 Investor Takeaway
Jagsonpal Pharmaceuticals reported standalone revenue from operations of Rs. 813.75 Million and total comprehensive income of Rs. 123.88 Million for Q2 FY27. For the half year ended September 30, 2026, standalone revenue reached Rs. 1,636.07 Million, compared to Rs. 1,500.77 Million in the previous year's comparable period.
⚖️ Strengths & Concerns

✅ Positives

  • Standalone revenue from operations for the half year increased to Rs. 1,636.07 Million, up from Rs. 1,500.77 Million YoY.
  • Standalone total comprehensive income for the half year increased to Rs. 256.71 Million, up from Rs. 235.96 Million YoY.

⚠️ Concerns

  • Standalone revenue from operations for Q2 FY27 decreased sequentially to Rs. 813.75 Million from Rs. 822.32 Million in Q1 FY27.
  • Standalone total comprehensive income for Q2 FY27 decreased sequentially to Rs. 123.88 Million from Rs. 132.83 Million in Q1 FY27.
📅 Company Track Record
In Q1 FY27, Jagsonpal Pharmaceuticals reported standalone net profit of Rs. 131.89 Million with revenue at Rs. 822.32 Million. Press releases mentioned Q2 FY27 consolidated revenue grew 29% to ₹964 Mn, driven by acquisitions, indicating a distinction between standalone and consolidated performance.

Based on publicly available historical data. For context only.

❓ Frequently Asked Questions
What was Jagsonpal Pharmaceuticals' standalone revenue from operations in Q2 FY27?
Jagsonpal Pharmaceuticals reported standalone revenue from operations of Rs. 813.75 Million for the quarter ended September 30, 2026 (Q2 FY27).
What was Jagsonpal Pharmaceuticals' standalone total comprehensive income for Q2 FY27?
The standalone total comprehensive income for Jagsonpal Pharmaceuticals for the quarter ended September 30, 2026, was Rs. 123.88 Million.
What was the Basic EPS for Jagsonpal Pharmaceuticals in Q2 FY27?
The Basic Earnings Per Share (EPS) for Jagsonpal Pharmaceuticals for the quarter ended September 30, 2026, was Rs. 1.91.
What was Jagsonpal Pharmaceuticals' standalone revenue for the half year ended September 30, 2026?
Jagsonpal Pharmaceuticals' standalone revenue from operations for the half year ended September 30, 2026, was Rs. 1,636.07 Million.
How did Jagsonpal Pharmaceuticals' H1 FY27 standalone total comprehensive income compare to H1 FY26?
Jagsonpal Pharmaceuticals' standalone total comprehensive income for H1 FY27 was Rs. 256.71 Million, an increase from Rs. 235.96 Million in H1 FY26.

Questions based on this BSE filing only. For information purposes.

⚠️ For Information Only — Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector — takes 5 seconds.